NeuroSense Therapeutics (NRSN) said Monday it received a written notice from Nasdaq that the company had regained compliance with the $2.5 million minimum stockholders' equity requirement.
The company said it closed a $5 million financing in December.
Shares of NeuroSense were up nearly 4.2% in recent trading.
Price: 1.24, Change: +0.05, Percent Change: +4.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.